

# Reumatología Clínica

## Similitudes y diferencias entre la Espondiloartritis Axial No Radiográfica y Radiográfica: La perspectiva del paciente del Atlas 2017

--Borrador del manuscrito--

<b>Número del manuscrito:</b>	REUMATOLCLIN-D-20-00212R1
<b>Tipo de artículo:</b>	Original
<b>Palabras clave:</b>	Espondiloartritis Axial, Espondiloartritis Axial no-radiográfica, Retraso Diagnóstico, Terapia Farmacológica, Medidas informadas por el Paciente
<b>Autor correspondiente:</b>	Marco Garrido-Cumbrera, Ph.D. Universidad de Sevilla Seville, Sevilla SPAIN
<b>Primer autor:</b>	Marco Garrido-Cumbrera
<b>Orden de autores:</b>	Marco Garrido-Cumbrera Jordi Gratacos-Masmitja Eduardo Collantes-Estevez Pedro Zarco-Montejo Carlos Sastre Sergio Sanz-Gómez Victoria Navarro-Compan
<b>Región de origen del manuscrito:</b>	SPAIN
<b>Resumen:</b>	<p><b>Objetivo:</b> La espondiloartritis axial no radiográfica (EspA-ax-nr) está considerada junto con la EspA-ax radiográfica (EspA-ax-r) como parte del mismo espectro de enfermedades. Sin embargo, se desconoce su comprensión por parte de los pacientes. El objetivo es describir la entidad EspA-ax-nr desde la perspectiva del paciente.</p> <p><b>Métodos:</b> El Atlas 2017, promovido por la Coordinadora Española de Asociaciones de Espondiloartritis (CEADE), tiene como objetivo la comprensión integral la realidad de los pacientes EspA-ax. Se realizó una encuesta transversal on-line de pacientes españoles no seleccionados con diagnóstico de EspA-ax. Se pidió a los participantes que informaran de su diagnóstico. Se compararon las características sociodemográficas y clínicas, así como medidas informadas por pacientes entre aquellos que declararon EspA-ax-nr y EspA-ax-r.</p> <p><b>Resultados:</b> Participaron 634 pacientes de EspA-ax. Edad media 45,7±10,9 años, 50,9% mujeres y 36,1% con educación universitaria. 35 (5,2%) reportaron EspA-ax-nr. En comparación con los pacientes de EspA-ax-r, los que tenían EspA-ax-nr eran más frecuentemente mujeres (48,6% vs 91,4%, p&lt;0,001), tenían mayor retraso en el diagnóstico (10,1±8,9 vs 8,5±7. 6 años), mayor malestar psicológico (GHQ-12: 7,5±4,9 vs 5,6±4,4) y un grado similar de actividad de la enfermedad (BASDAI: 5,7±2,1 vs 5,7±2,0), y desempleo (20,0% vs 21,6%). El 20,0% de EspA-ax-nr recibió biológicos vs 36,9% de EspA-ax-r (p=0,043). Las visitas al reumatólogo en el último año fueron similares (3,8±4,5 vs 3,2±3,8), mientras que fueron mucho más altas dentro de EspA-ax-nr para el médico de cabecera (8,0±10,7 vs 4,9±13,3 p=0,003).</p> <p><b>Conclusión:</b> Ambos grupos informaron de tendencias similares, con la excepción de que EspA-ax-nr es más frecuente en las mujeres, asociada a menor edad, mayor retraso diagnóstico y menor uso de terapia biológica.</p>

## **Modificaciones efectuadas al artículo:**

**Sugerencia 1: si es posible, aportar el dato de diagnóstico concomitante de fibromialgia, que podría interferir en los resultados de los PROM y en el retraso diagnóstico. Además, es llamativo que el 91.4% de las No radiográficas sean mujeres.**

*Modificación:* Hemos incluido los datos de los pacientes con EspA-ax que además padecían fibromialgia. Como se comprueba, el porcentaje de pacientes con fibromialgia es similar en ambos grupos (No-radiográficos y Radiográficos) y está en consonancia con estudios previos. Esto ha quedado descrito en el apartado de discusión.

En el estudio, se observó un alto porcentaje de mujeres en ambos grupos (No-radiográficos y Radiográficos), lo cual es habitual en los estudios que se realizan a través de encuestas online (ver Smith & Smith. Does gender influence online survey participation?: A record-linkage analysis of university faculty online survey response behavior. 2008). No obstante, la proporción de mujeres fue sustancialmente mayor en el grupo de EspA-ax-nr, lo cual también va acorde a los resultados en otras cohortes (SPACE, GESPIC).

*Localización:* Página 10, línea 12 y Página 12, última línea

**Sugerencia 2: aportar una explicación del porqué la EspAx No radiográfica supone en este trabajo solo entorno al 5% del conjunto de las EspAx, comparado con los datos publicados.**

*Modificación:* Un posible factor que podría explicar esto es que el reclutamiento se realizó desde la Coordinadora Española de Asociaciones de Espondiloartritis (CEADE). Por ello, no se puede inferir ningún planteamiento sobre la prevalencia de EspA-ax-nr en relación a la de EA. En el apartado de discusión se ha aclarado este punto.

*Localización:* Página 9, línea 22

**Sugerencia 3: En el resumen en español, cambiar en Métodos la abreviatura axSpA por EspAax**

*Modificación:* Hemos corregido este acrónimo siguiendo con las recomendaciones del consenso ASAS para la nomenclatura de espondiloartritis en español.

*Localización:* Abstract en castellano.

# Ética de la publicación

1. ¿Su trabajo ha comportado experimentación en animales?:

**No**

2. ¿En su trabajo intervienen pacientes o sujetos humanos?:

**Sí**

- Si la respuesta es afirmativa, por favor, mencione el comité ético que aprobó la investigación.:  
**Todos los participantes firmaron un consentimiento informado previo a su participación en la investigación. Como el diseño de la investigación (una encuesta transversal) no implicaba intervenciones, no se requirió la aprobación de un comité ético especializado.**

- Si la respuesta es afirmativa, por favor, confirme que los autores han cumplido las normas éticas relevantes para la publicación. :

**Sí**

- Si la respuesta es afirmativa, por favor, confirme que los autores cuentan con el consentimiento informado de los pacientes. :

**Sí**

3. ¿Su trabajo incluye un ensayo clínico?:

**No**

4. ¿Todos los datos mostrados en las figuras y tablas incluidas en el manuscrito se recogen en el apartado de resultados y las conclusiones?:

**Sí**

**Title:** Similarities and Differences between Non-radiographic and Radiographic Axial Spondyloarthritis: The Patient Perspective from the Spanish Atlas.

**Authors:**

M. Garrido-Cumbrera<sup>a,b</sup>, [mcumbrera@us.es](mailto:mcumbrera@us.es), ORCID 0000-0001-9727-1189

J. Gratacos<sup>c</sup>, [jgratacosmas@gmail.com](mailto:jgratacosmas@gmail.com), ORCID 0000-0003-4007-4103

E. Collantes-Estevez<sup>d,e</sup>, [edcollantes@yahoo.es](mailto:edcollantes@yahoo.es), ORCID 0000-0002-7647-6289

P. Zarco<sup>f</sup>, [pzarco@fhalcorcon.es](mailto:pzarco@fhalcorcon.es), ORCID 0000-0002-3039-187X

C. Sastre<sup>g</sup>, [carlos.sastre@novartis.com](mailto:carlos.sastre@novartis.com), ORCID 0000-0002-1577-7838

S. Sanz-Gómez<sup>a</sup>, [ssanz1@us.es](mailto:ssanz1@us.es), ORCID 0000-0001-6801-0836

V. Navarro-Compán<sup>h</sup>, [mvictoria.navarro@gmail.com](mailto:mvictoria.navarro@gmail.com), ORCID 0000-0002-4527-852X

**Author affiliations:**

<sup>a</sup>Health & Territory Research, Universidad de Sevilla, Seville, Spain

<sup>b</sup>Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain

<sup>c</sup>Hospital Universitari Parc Taulí, I3PT, UAB, Barcelona, Spain

<sup>d</sup>Reina Sofia University Hospital, Cordoba, Spain

<sup>e</sup>Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordova, Spain

<sup>f</sup>Hospital Universitario Fundación Alcorcón, Madrid, Spain

<sup>g</sup>Novartis Spain, Barcelona, Spain

<sup>h</sup>Hospital Universitario La Paz, IdiPaz, Madrid, Spain

**Corresponding author:**

Marco Garrido Cumbrera, [mcumbrera@us.es](mailto:mcumbrera@us.es)

Health & Territory Research (HTR), Centro de Investigación, Tecnología e Innovación  
Manuel Losada Villasante (CITIUS III), Universidad de Sevilla. C/ Doctor Rafael  
Martínez Domínguez, SN, 41009 Sevilla, Spain.

**Author contributions:**

M. Garrido-Cumbrera made substantial contributions to study conception and design and to the interpretation of the data. He contributed to the writing of the manuscript and approved the last version to be published.

J. Gratacos made substantial contributions to study conception and design and to the interpretation of the data. He contributed to the writing of the manuscript and approved the last version to be published.

E. Collantes-Estevez made substantial contributions to study conception and design and to the interpretation of the data. He contributed to the writing of the manuscript and approved the last version to be published.

P. Zarco made substantial contributions to study conception and design and to the interpretation of the data. He contributed to the writing of the manuscript and approved the last version to be published.

C. Sastre made substantial contributions to study conception and design and to the interpretation of the data. He contributed to the writing of the manuscript and approved the last version to be published.

S. Sanz-Gómez made substantial contributions to study conception and design and to the interpretation of the data. He contributed to the writing of the manuscript and approved the last version to be published.

V. Navarro-Compán made substantial contributions to study conception and design and to the interpretation of the data. She contributed to the writing of the manuscript and approved the last version to be published.

**Funding:**

The Atlas 2017 study was supported by Novartis Farmacéutica Spain, which in no mean affected the analysis or interpretation of results.

**Conflict of interest:**

Dr. Jordi Gratacós has received unrelated honoraria or research grants from Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, and UCB.

Dr. Eduardo Collantes-Estévez has received unrelated honoraria or research grants from Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, and UCB.

Mr. Carlos Sastre is an employee of Novartis Farmacéutica Spain.

Dr. Victoria Navarro-Compán has received unrelated honoraria or research grants from Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche, and UCB.

The rest of the authors declare that they have no conflict of interest to disclose.

**Acknowledgments:**

Mr. José Correa-Fernández, from Health and Territory Research (HTR), Universidad de Sevilla, carried out the data analysis.

**Abstract:**

**Aim:** Although non-radiographic axial spondyloarthritis (nr-axSpA) is well understood within health institutions, being considered along with radiographic axSpA (r-axSpA) as part of the same disease spectrum, patient understanding is unknown. The aim is to describe the patient's knowledge of the nr-axSpA entity.

**Methods:** Atlas 2017, promoted by the Spanish Federation of Spondylarthritis Associations (CEADE), aims to comprehensively understand the reality of axSpA patients from a holistic approach. A cross-sectional on-line survey of unselected patients with self-reported axSpA diagnosis from Spain was conducted. Participants were asked to report their diagnosis. Socio-demographic, disease characteristics and patient-reported outcomes (PROs) were compared between those patients self-reporting as nr-axSpA and r-axSpA.

**Results:** 634 axSpA patients participated. Mean age  $45.7 \pm 10.9$  years, 50.9% female and 36.1% university-educated. 35 (5.2%) self-reported as nr-axSpA. Compared to r-axSpA patients, those with nr-axSpA were more frequently women (48.6% vs 91.4%,  $p < 0.001$ ), had longer diagnostic delay ( $10.1 \pm 8.9$  vs  $8.5 \pm 7.6$  years), higher psychological distress (GHQ-12:  $7.5 \pm 4.9$  vs  $5.6 \pm 4.4$ ) and similar degree of disease activity (BASDAI:  $5.7 \pm 2.1$  vs  $5.7 \pm 2.0$ ), and unemployment rates (20.0% vs 21.6%). 20.0% of nr-axSpA received biologics vs 36.9% of r-axSpA,  $p = 0.043$ . Visits to the rheumatologist in the past year were similar in both groups ( $3.8 \pm 4.5$  vs  $3.2 \pm 3.8$ ), while GP visits were much higher within nr-axSpA ( $8.0 \pm 10.7$  vs  $4.9 \pm 13.3$ ,  $p = 0.003$ ).

**Conclusion:** For the first time, nr-axSpA characteristics and PROs have been analyzed from the patient's perspective. Both groups reported similar trends with the exception of nr-axSpA being more frequently women, younger, having longer diagnostic delay and lower use of biologic therapy.

**Key words:** ankylosing spondylitis, diagnosis-related groups, delayed diagnosis, pharmacologic therapy, patient-reported outcomes



## ***Introduction***

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that encompasses radiographic (r-axSpA, traditionally known as ankylosing spondylitis [AS]) and non-radiographic (nr-axSpA) forms. This inflammatory disease can lead to chronic pain, structural damage, and disability <sup>1</sup>. In particular, physical restrictions and worsening quality of life caused by the disease are closely related to the limitations that patients face in their professional, social and family spheres <sup>2,3</sup>.

During the last decades, there has been a tremendous increase in the volume of research on axSpA. However, its non-radiographic form has been the focus of attention in the recent years. Unlike AS, which was first described around 1900 <sup>4</sup>, nr-axSpA was first described in the 60s <sup>5</sup>. As a silent form of axSpA that courses without structural damage in sacroiliac joints or the rest of the spine, nr-axSpA diagnosis has implied a recent challenge for Rheumatology. Up to date, no study has been able to report the incidence or prevalence rates of nr-axSpA <sup>6</sup>.

Since the appearance of MRI scan and its possibilities, there has been an overemphasis on radiological criteria in the diagnosis of spondyloarthritis <sup>7</sup>. This has supported the advance in the research of the radiographic forms of axSpA at the expense of its non-radiographic forms. Either way, MRI by itself cannot serve as the touchstone to make a diagnosis of early axSpA due to limitations in both sensitivity and specificity, and because even an advanced imaging modality cannot capture the entire clinical spectrum of the condition <sup>8</sup>.

As a result, before the new Assessment of Spondyloarthritis International Society (ASAS) criteria, the previous classification criteria for SpA did not take into account the existence of non-radiographic forms, i.e. the 1984 Modified New York Criteria, the 1990 AMOR Criteria or the 1991 European Spondyloarthropathy Study Group criteria <sup>9</sup>. It has not been until 2009 when the ASAS published new classification criteria to reliably classify axSpA

in both its radiographic and non-radiographic forms <sup>10</sup> with solid sensibility and specificity (82.9% and 84.4% respectively) <sup>11</sup>. This is the first set of classification criteria that introduces nr-axSpA as a differentiated stage of the axSpA continuum <sup>7</sup>.

This way, it is not surprising that patients with r-axSpA and nr-axSpA experience a similar burden of disease, reporting similar levels of disease activity and functional limitation <sup>12</sup>, mental health <sup>13</sup> and overall level of quality of life <sup>14</sup>. Research has also informed of substantial work impact on nr-axSpA patients, not significantly different from those of r-axSpA patients <sup>15</sup>.

The concept of nr-axSpA was coined a decade ago after the development of ASAS classification criteria for axSpA. After this period, nr-axSpA entity seems to be well understood and implemented within rheumatology and drug regulatory agencies. Nevertheless, the understanding and knowledge of nr-axSpA by patients is unknown as specific research on the subject is non-existent. The purpose of the present study is to describe the characteristics and patient-reported outcomes (PROs) of patients who self-reported as nr-axSpA and compare them to those who self-reported as r-axSpA, using data from the Spanish Atlas.

## ***Materials and Methods***

### *Working Group*

Atlas 2017 is an initiative of the Spanish Federation of Spondylarthritis Associations (CEADE), carried out by Health & Territory Research (HTR) of the University of Seville and the Max Weber Institute, with the collaboration of the Spanish Society of Rheumatology (SER) and sponsored by Novartis Farmacéutica, Spain.

## *Design and Survey Development*

A patient questionnaire was designed for individuals suffering from axSpA based on expert opinion of a panel of rheumatologists and patient research partners with axSpA. The questionnaire collected data regarding the following areas: diagnosis, treatment, comorbidity, employment, functional limitation and psychological health.

The interest of the Atlas was to collect a real-world sample, rather than relying on patients collected in clinical settings, a method that is subject to sampling bias as patients recruited this way are typically “good patients” with better treatment adherence and in close contact with the health system. For this reason, the distribution of the patient survey was done through CEADE, which forwarded it to local axSpA-specific patient organizations. Participating patients could send the survey to family and friends with the disease, using a non-probabilistic snowball sampling method.

The online questionnaire surveying periods lasted from May 1 to August 15, 2016. After the validation and normalization of the information, the sample consisted of a total of 680 patients who responded to the majority of the questionnaire (completion rate was higher than 75%; see sample flow chart in Figure 1). An extensive report of the Atlas 2017 method can be consulted for further information <sup>16</sup>.

*Figure 1.* Flow chart of patients included in the study from the Spanish Atlas database.

Inclusion criteria were age of 18 years or older (adults), living in Spain during the survey and a self-reported diagnosis of axSpA. Diagnosis and type of condition was assessed by a multiple choice question at the beginning of the questionnaire which stated “Are you diagnosed with...?” followed by the following five options: “Ankylosing Spondylitis”, “Axial Spondyloarthritis”, “Non-radiographic Axial Spondyloarthritis”, “Peripheral Spondyloarthritis” and “None of the above”. The selection of the latter option (“None of the

above”) prevented the person from continuing to fill in the questionnaire and any data entered until that point was thus automatically discarded. For this study, patients who reported self-diagnosis of Peripheral Spondyloarthritis were removed from the sample. Two groups were considered, the r-axSpA group, comprised of those patients self-reporting diagnosis as either “Ankylosing Spondylitis” or “Axial Spondyloarthritis” and the nr-axSpA group, composed those declaring “Non-radiographic Axial Spondyloarthritis” as their diagnosis.

### *Supplementary indices*

In addition, a range of supplementary measures were collected in the questionnaire to assess specific areas:

1. *BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)*: A validated self-administered questionnaire assessing disease activity in patients with axSpA <sup>17</sup>.
2. *Spinal Stiffness Index*: this index, based on the ASAS concept of spinal stiffness <sup>18</sup> was developed specifically for this study, assesses the degree of stiffness experienced by patients in the spinal column, distinguishing between the cervical, dorsal, and lumbar areas. Possible responses range from least to most affected column (1: without stiffness, 2: mild stiffness, 3: moderate stiffness, and 4: severe stiffness), total scores are obtained by adding together the responses in each of the three areas of the spine without weighting resulting in a scale ranging from 3 to 12.
3. *Functional Limitation Index*: this index, developed specifically for this study, assesses the degree of functional limitation in 18 daily life activities (dressing, bathing, showering, tying shoe laces, moving about the house, climbing stairs, getting out of bed, using the bathroom, shopping, preparing meals, eating, household cleaning, walking down the street, using public transportation, driving, going to the doctor, doing physical exercise, having sex). The activities were selected and validated by the scientific committee of the Atlas taking into

account the opinion of patient research partners. Each of these 18 daily life activities was assigned as 0 for no limitation, 1 low limitation, 2 medium limitation and 3 high limitations, resulting in values between 0 and 54. A total score from 0 and 18 was considered low limitation, between 18 and 36 medium limitation and between 36 and 54 high limitation.

4. *GHQ-12 (General Health Questionnaire–12)*: This questionnaire evaluates psychological distress using 12 items. For the present study, these were transformed into a dichotomous score (0-0-1-1), called the GHQ score. The cut-off point of 3 implied those with a score of 3 or more may be experiencing psychological distress <sup>19</sup>.

### *Statistical Analysis*

For the analyses, nr-axSpA group was compared with a r-axSpA group, combining the data from the AS and axSpA conditions (Figure 1). Sociodemographic, disease-related, employment status, healthcare utilization and treatment variables were compared between groups patients using Mann-Whitney, Kruskal-Wallis and Chi-square tests to assess the statistical significance of the observed differences between both groups.

### **Results**

A total of 680 people participated in the Atlas 2017 survey of which 46 participants who self-reported Peripheral axSpA were discarded, resulting in 634 being included in this study. For this sample of 634 participants, mean age was  $45.7 \pm 10.9$  years, 50.9% were female and 36.1% university-educated. 35 (5.5%) self-reported a diagnosis of nr-axSpA while the remaining 599 (94.5%) were classified as r-axSpA as they self-reported either AS (96.5%) or axSpA (3.5%). The vast majority of patients with self-reported nr-axSpA were women (91.4%), compared to 48.6% of women across patients with self-reported r-axSpA (Table 1).

Of the people with self-reported r-axSpA and nr-axSpA who completed the BASDAI scale the average score was exactly the same (5.7) which implies that the average disease activity was high (exceeding 4 which is the cut-off point indicating high disease activity score, according to rheumatologic standards) for both groups. The mean diagnostic delay declared by people with self-reported nr-axSpA was more than a year and a half longer than among those with self-reported r-axSpA (10.1 compared to 8.5). Patients with self-reported nr-axSpA showed higher levels of psychological distress, averaging at 7.5 at the GHQ-12 score whereas patients with other forms of self-reported r-axSpA averaged 5.6 (Table 1).

Distribution of self-reported r-axSpA and nr-axSpA patients regarding active and inactive population was equivalent, with similar unemployment rates. Out of the inactive population, two thirds of patients with self-reported nr-axSpA were on temporary sick leave at the moment of the survey compared to one quarter of patients with self-reported r-axSpA (Table 2).

Patients with self-reported nr-axSpA reported equivalent distributions regarding their disease-related appointments to healthcare specialists in the year prior to the survey with few exceptions. Patients with nr-axSpA reported an increased frequency of visits to orthopedic specialist and general practitioner, more than double to the physiotherapist and almost triple to the gastroenterologist (Table 3). Regarding the number of medical test taken by patients with self-reported nr-axSpA, similar frequencies were reported along both self-reported nr-axSpA and r-axSpA patients (Table 4).

With regard to pharmacologic treatments administered to patients, similar NSAID and DMARD, usage rates were reported for both groups (r-axSpA and nr-axSpA). With respect to biologic treatment, there were differences, as more than a third of self-reported r-axSpA patients declared to be taking biologics as opposed to the fifth of self-reported nr-axSpA patients that declared to be taking biologics (Table 5).

## *Discussion*

There is a discussion whether nr-axSpA and r-axSpA are different clinical entities or different stages of the same disease<sup>20</sup>. The fact that most of the studies report about 10% to 40% of patients with nr-axSpA to progress to r-axSpA over a period of two to ten years<sup>21</sup>, and that both entities share similar disease characteristics incline researchers towards the approach of being part of the same disease spectrum. According to published data, radiographic and non-radiographic forms of spondyloarthritis mainly differ in presence of substantial sacroiliac joints damage in r-axSpA forms and a higher proportion of females, young patients and elevated C-reactive protein (CRP) serum levels among nr-axSpA forms<sup>22</sup>. However, r-axSpA and nr-axSpA seem to have more aspects in common than differentials. Research from several cohorts such as the DESIR<sup>23</sup> or SPACE<sup>24</sup> have found similarities between both groups regarding symptom duration, age at onset of first symptoms, prevalence of HLA-B27 carriership<sup>25</sup>, patient-reported outcomes, and the presence of extra-articular or peripheral manifestations<sup>26,27</sup>. They also share a common course, as there are similarities in their disease development. As found out by the GESPIC cohort, both nr-axSpA and r-axSpA share factors associated to radiographic progression such as presence of syndesmophytes and acute phase reactants<sup>28</sup>. However, most of these previous data with regard to nr-axSpA comes from studies conducted in central or northern Europe and focused on the clinical aspects of the disease.

The Atlas places its focus of interest on Spain, a country in the Mediterranean zone, with a representative sample of the different Autonomous Communities and not only exploring clinical data but also considering functional limitation in daily life, work life and mental health, from patient's perspective. In this study, nr-axSpA account for only about 5% of all axSpA. One possible factor that could explain this low percentage is that the recruitment was done through the national patient organization (CEADE) and therefore, it is not possible to infer any consideration regarding the prevalence of nr-axSpA in relation to that of axSpA. Additionally,

women comprised a substantial percentage of the sample, which is common in studies conducted through online surveys<sup>29</sup>.

In spite of this, results of the present study including self-reported nr-axSpA and r-axSpA patients are consistent with published data collected directly in clinical settings. Patients with self-reported nr-axSpA informed of trends similar to that of patients with r-axSpA in the following aspects explored: sociodemographic, employment, healthcare utilization, disease activity, spinal stiffness and pharmacological treatments. Regarding socio-demographic, disease characteristics and PROs, the only significant observed differences were that compared with patients with r-axSpA, those with nr-axSpA had a higher proportion of females, greater functional limitation in daily life activities and were more frequently on temporary sick leave. In addition, a trend toward a longer diagnostic delay and worst mental health status in patients with nr-axSpA was also observed. We examined whether the presence of fibromyalgia could have affected PROs or diagnostic delay. However, it is unlikely that the presence of fibromyalgia could have altered our results because the percentage of fibromyalgia reported was within the published values of axSpA 30,31 and, additionally, there were no statistically significant differences in the distribution of fibromyalgia between the two groups.

Results of this Spanish Atlas survey are aligned with those of previous studies like that of the GESPIC cohort, in which, of all aspects assessed between radiographic and non-radiographic forms of axSpA, only a difference in gender ratios was found (women were more likely than men to have a diagnosis of nr-axSpA)<sup>22</sup>. Another study, also carried out in Germany in a sample of 100 patients (44% of them with a non-radiographic diagnosis) concluded that even if nr-axSpA and axSpA patients differed in signs of inflammation, they showed no differences regarding health status and disease activity. The same study also reported a higher prevalence of nr-axSpA in women<sup>12</sup>. On the other hand, patients with nr-axSpA in the Atlas reported higher functional limitation in daily activities. These results differ with data from other



populations such as SPACE or DESIR, in which no differences between groups were found for functional limitation. This may be explained by the different instrument employed to assess this outcome and also by the difficulties of patients with shorter disease duration to cope with the disease, as in our study the nr-axSpA group had a significantly shorter disease duration compared to that of SPACE and DESIR. In addition, patients with nr-axSpA reported to be on temporary sick leave more frequently than patients with r-axSpA. Similarly, to functional limitation, this could also be related to the difficulties to cope with the disease, as they are younger and so entering the labour market. Furthermore, in our study patients with self-reported nr-axSpA declared a higher level of psychological stress than their radiographic counterparts. However, sample size for that comparison was particularly low in the case of self-reported nr-axSpA so statistical results may be subject to sample bias, and can compromise the conclusions drawn from these results. In any case, other studies that have assessed psychological burden have not found statically significant differences between nr-axSpA and axSpA groups <sup>26</sup>.

Another aspect standing out in patients with self-reported nr-axSpA is a tendency for longer diagnostic delay with respect to those with self-reported r-axSpA, probably related to the absence of evidence of radiographic damage. Paradoxically, if we assume that some of the non-radiographic patients' progress to a radiographic stage, for sure a number of r-axSpA patients were only diagnosed at the beginning of their radiographic stage. This means that current r-axSpA patients could have go through a previous non-radiographic phase that was at the time totally unknown to rheumatologists and was, therefore, ignored and deprived of an early diagnosis and treatment.

As for the medical test used for diagnosis, both groups followed a similar diagnostic pathway with the exception of MRI scan, more frequently used in the nr-axSpA group. This is understandable as the rheumatologist with the support of the radiologist would probably run various scans in order to really determine whether or not there was radiographic damage.

Statistically significant differences also arise for the radionuclide scintigraphy option, although the frequency of use of this medical test is too low for drawing conclusions on a sample this size.

Regarding healthcare utilization, both groups reported similar profiles. However, the group self-reporting as nr-axSpA declared to visit general practitioners, orthopedic specialists and physiotherapists more frequently than their counterparts. This need to visit more medical specialists could be due to poorer disease outcomes. On the other hand, nr-axSpA patients reported less visits to psychologist/psychiatrist in the year prior to the survey, despite declaring greater psychological distress. This would point to an unmet need for psychological support for this group of patients.

Other important idea suggested by the data collected is that, despite that self-reported nr-axSpA patients have similar levels of disease activity and spinal stiffness than r-axSpA patients, they are not receiving biologic treatments at an equivalent rate.

### *Limitations*

However, this study has some limitations. First, all data of the survey was self-reported, and did not attempt to confirm participant diagnosis nor to support participant responses with clinician reported assessments. As such, clinical data such as the BASDAI or GHQ-12 scores, as well as the report of extra-articular manifestations may suffer from response bias. Nevertheless, the sample characteristics were consistent with previous cohorts including patients with confirmed axSpA and nr-axSpA<sup>12,22,25,32,33</sup>, and as the aim of the survey was to better understand the patient perspective, direct feedback was preferred. Secondly, as the sample was unselected there was no means to ensure the size of the nr-axSpA subgroup. The final sample had in total 35 patients with self-reported nr-axSpA, which precluded the possibilities of the inferential analysis. Low sample size of the nr-axSpA group could be due to

either misdiagnosis or patient misunderstanding of the disease, although women, well-represented in the sample, are more likely to be knowledgeable about their health status. Still, the descriptive analysis supports the goal of our study: to check the health and disease status of a neglected population of nr-axSpA patients.

### ***Conclusion***

For the first time, nr-axSpA disease characteristics and PROs, as well as patients' journey towards diagnosis, healthcare and treatments have been analysed from the patient's perspective. Results show a high burden of disease of nr-axSpA patients, comparable to that of the r-axSpA group, with similar work impact and use of healthcare resources, suggesting that both nr-axSpA and r-axSpA are associated to an equivalent level of suffering. Nr-axSpA patients reported the same level of disease activity, and similar levels of spinal stiffness, compared to r-axSpA patients, even if they are not receiving the same rate of biologics treatments.

Further research is needed on clinical aspects and impact on daily life aspects for a better understanding of the patient experience with the condition and the improvement of their healthcare, management and quality of life.

### ***References***

1. Sieper, J. & Poddubnyy, D. Axial spondyloarthritis. *Lancet* **390**, 73–84 (2017).
2. Song, Y., Wang, C. & Chen, H. Functional limitation and associated factors in outpatients with ankylosing spondylitis in Southwest China. *Clin. Rheumatol.* **36**, 871–7 (2017).
3. Shen, C.-C. *et al.* Risk of Psychiatric Disorders following Ankylosing Spondylitis: A Nationwide Population-based Retrospective Cohort Study. *J. Rheumatol.* **43**, 625–31 (2016).

4. Sieper, J. & van der Heijde, D. Nonradiographic Axial Spondyloarthritis: New Definition of and Old Disease? *Arthritis Rheum.* **65**, 543–551 (2013).
5. Khan, M. A., Valkenburg, H. A. & Cats, A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. *Arthritis Rheum.* **28**, 40–43 (1985).
6. Bohn, R., Cooney, M., Deodhar, A., Curtis, J. R. & Golembesky, A. Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literature. *Clin. Exp. Rheumatol.* **36**, 263–274 (2018).
7. Malaviya, A. N., Rawat, R., Agrawal, N. & Patil, N. S. The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology. *Int. J. Rheumatol.* **2017**, 1–9 (2017).
8. Lukas, C., Cyteval, C., Dougados, M. & Weber, U. MRI for diagnosis of axial spondyloarthritis: Major advance with critical limitations ‘Not everything that glitters is gold (standard)’. *RMD Open* **4**, 1–9 (2018).
9. Lockwood, M. M. & Gensler, L. S. Nonradiographic axial spondyloarthritis. *Best Pract. Res. Clin. Rheumatol.* **31**, 816–829 (2017).
10. Banegas-Illescas, M. E., López-Menéndez, C., Rozas-Rodríguez, M. L. & Fernández-Quintero, R. M. New ASAS criteria for the diagnosis of spondyloarthritis: Diagnosing sacroiliitis by magnetic resonance imaging. *Radiologia* **56**, 7–15 (2014).
11. Rudwaleit, M. *et al.* The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann. Rheum. Dis.* **68**, 770–6 (2009).
12. Boonen, A. *et al.* The burden of non-radiographic axial spondyloarthritis. *Semin.*

- Arthritis Rheum.* **44**, 556–562 (2015).
13. Poddubnyy, D. *et al.* Similarities and differences between nonradiographic and radiographic axial spondyloarthritis. *Curr. Opin. Rheumatol.* **26**, 377–383 (2014).
  14. Kiltz, U. *et al.* Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? *Arthritis Care Res.* **64**, 1415–1422 (2012).
  15. van Hoesen, L., Boonen, A. E. R. C. H., Hazes, J. M. W. & Weel, A. E. A. M. Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain. *Arthritis Res. Ther.* **19**, 1–8 (2017).
  16. Garrido-Cumbrera, M. *et al.* Atlas of axial spondyloarthritis in Spain 2017: Study design and population. *Reumatol. Clin.* **15**, 127–132 (2019).
  17. Garrett, S. *et al.* A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J. Rheumatol.* **21**, 2286–91 (1994).
  18. Zochling, J. *et al.* ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann. Rheum. Dis.* **65**, 442–52 (2006).
  19. Cano, A. *et al.* Mental Health Screening in Primary Care: A Comparison of 3 Brief Measures of Psychological Distress. *Prim Care Companion J Clin Psychiatry* **3**, 206–210 (2001).
  20. Deodhar, A., Strand, V., Kay, J. & Braun, J. The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. *Ann. Rheum. Dis.* **75**, 791–794 (2016).
  21. Protopopov, M. & Poddubnyy, D. Radiographic progression in non-radiographic axial

- spondyloarthritis. *Expert Rev. Clin. Immunol.* **14**, 525–533 (2018).
22. Poddubnyy, D. *et al.* Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. *Ann. Rheum. Dis.* **70**, 1369–1374 (2011).
  23. Dougados, M. *et al.* The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. *Jt. Bone Spine* **78**, 598–603 (2011).
  24. van Lunteren, M. *et al.* In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. *J. Rheumatol.* **45**, 779–784 (2018).
  25. Baraliakos, X. & Braun, J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: What are the similarities and differences? *RMD Open* **1**, 8–11 (2015).
  26. Erol, K. *et al.* Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis. *Acta Reumatol. Port.* **43**, 32–39 (2018).
  27. de Winter, J. J., van Mens, L. J., van der Heijde, D., Landewé, R. & Baeten, D. L. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: A meta-analysis. *Arthritis Res. Ther.* **18**, 1–11 (2016).
  28. Poddubnyy, D. *et al.* Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. *Arthritis Rheum.* **64**, 1388–1398 (2012).
  29. Smith, G. & Smith, W. G. *Does gender influence online survey participation?: A record-linkage analysis of university faculty online survey response behavior.* (2008).

30. Salaffi, F. *et al.* Fibromyalgia in patients with axial spondyloarthritis: Epidemiological profile and effect on measures of disease activity. *Rheumatol. Int.* **34**, 1103–1110 (2014).
31. Rifbjerg-Madsen, S. *et al.* Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. *PLoS One* **12**, 1–16 (2017).
32. Malaviya, A. N., Kalyani, A., Rawat, R. & Gogia, S. B. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. *Int. J. Rheum. Dis.* **18**, 736–741 (2015).
33. Poddubnyy, D. & Sieper, J. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. *Curr. Opin. Rheumatol.* **26**, 377–383 (2014).

## Tables

*Table 1.* Sociodemographic characteristics and patient-reported outcomes of patients with self-reported nr-axSpA (N: 35, unless other specified) and r-axSpA (N: 599, unless other specified)

<i>Variable</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
Age (years)	42.1 ± 8.8	46.0 ± 10.9	0.045*
Gender (female)	32 (91.4)	291 (48.6)	<0.001** *
Education level (University)	17 (48.6)	212 (35.4)	0.351

Marital status (Married)	20 (57.1)	434 (72.5)	0.223
Disease duration	14.1 ± 10.1 N: 18	21.8 ± 12.1 N: 486	<0.001** *
HLA B27	20 (64.5) N: 31	350 (75.9) N: 461	0.155
BASDAI (0-10)	5.7 ± 2.1 N: 18	5.7 ± 2.0 N: 368	0.792
High BASDAI (≥ 4)	15 (83.3) N: 18	294 (79.9) N: 368	0.721
Spinal Stiffness Index (3-12)	6.5 ± 2.5 N: 24	7.5 ± 2.7 N: 437	0.053
Functional Limitation Index (0-54)	45.6 ± 10.4	42.1 ± 10.0 N: 531	0.007**
GHQ-12 (0-12)	7.5 ± 4.9 N: 20	5.6 ± 4.4 N: 418	0.087
Anxiety	6 (17.1)	116 (19.4)	0.746
Depression	5 (14.3)	86 (14.4)	0.991
Fibromyalgia	4 (11.4)	44 (7.3)	0.375
Diagnostic delay (years)	10.1 ± 8.9 N: 32	8.5 ± 7.6 N: 482	0.193

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level



Table 2. Employment status of patients with self-reported nr-axSpA (N: 35) and r-axSpA (N: 599)

<i>Employment Status</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
<i>Active</i>	20 (57.1)	370 (64.5)	
Employed	16 (80.0)	290 (78.4)	0.864
Unemployed	4 (20.0)	80 (21.6)	
<i>Inactive</i>	15 (42.9)	204 (35.5)	
Temporary sick leave	10 (66.6)	47 (23.0)	0.006**
Permanent sick leave	3 (20.0)	55 (27.0)	
Retired	0 (0.0)	59 (28.9)	
Early retired	0 (0.0)	9 (4.4)	
Homemaker	1 (6.7)	26 (12.7)	
Student	1 (6.7)	8 (3.9)	

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

Table 3. Specialists appointments in the past 12 months of patients with self-reported nr-axSpA (N: 35) and r-axSpA (N: 599)

<i>Specialist Appointments</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
--------------------------------	---	---	----------------

Rheumatologist	3.8 ± 4.5	3.2 ± 3.8	0.377
General Practitioner	8.0 ± 10.7	4.9 ± 13.3	0.003**
Clinical nurse	2.0 ± 4.3	2.1 ± 8.4	0.873
Orthopedic specialist	0.9 ± 2.0	0.5 ± 2.0	0.003**
Physiotherapist	14.3 ± 28.3	6.4 ± 19.0	0.012*
Ophthalmologist	1.0 ± 1.8	0.8 ± 2.2	0.135
Pulmonologist	0.2 ± 0.6	0.2 ± 0.8	0.462
Cardiologist	0.2 ± 1.0	0.2 ± 0.8	0.574
Psychologist	1.4 ± 3.3	2.0 ± 9.9	0.034*
Gastroenterologist	0.142 ± 0.4	0.058 ± 0.5	0.002**

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

Table 4. Medical test undertaken before diagnosis of patients with self-reported nr-axSpA (N: 35) and r-axSpA (N: 599)

<i>Medical test</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
X-rays	3.8 ± 4.5	3.2 ± 3.8	0.377
MRI	1.7 ± 2.5	0.6 ± 1.4	<0.001***
Ultrasound scan	0.4 ± 0.7	0.3 ± 0.8	0.051
Radionuclide scintigraphy	0.2 ± 0.5	0.1 ± 0.4	0.014*
CT scan	0.03 ± 0.2	0.04 ± 0.3	0.911

Blood test	3.8 ± 5.4	3.1 ± 3.8	0.947
Urine test	1.9 ± 2.8	1.9 ± 2.9	0.794

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

*Table 5.* Pharmacological treatment undertaken in the past 12 months of patients with self-reported nr-axSpA (N: 35, unless other specified) and r-axSpA (N: 599, unless other specified)

<i>Pharmacological Treatment</i>	<i>Self-reported nr-axSpA (N: 35)</i>	<i>Self-reported r-axSpA (N: 599)</i>	<i>p-value</i>
	<i>mean ± SD or n(%)</i>	<i>mean ± SD or n(%)</i>	
NSAID <sup>†</sup>	22 (62.9)	340 (56.8)	0.479
DMARD <sup>‡</sup>	5 (14.3)	131 (21.9)	0.288
Biologic	7 (20.0)	221 (36.9)	0.043*

<sup>†</sup>NSAID: Non-Steroidal Anti-Inflammatory Drug

<sup>‡</sup>DMARD: Disease-Modifying Anti-Rheumatic Drug

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

### ***Figure legends***

*Figure 1.* Flow chart of patients included in the study from the Spanish Atlas database.

AxSpA: axial Spondyloarthritis

Nr-axSpA: non-radiographic axial Spondyloarthritis




Figure 1 - Flow chart.png

**Abstract:**

**Aim:** Although non-radiographic axial spondyloarthritis (nr-axSpA) is well understood within health institutions, being considered along with radiographic axSpA (r-axSpA) as part of the same disease spectrum, patient understanding is unknown. The aim is to describe the patient's knowledge of the nr-axSpA entity.

**Methods:** Atlas 2017, promoted by the Spanish Federation of Spondylarthritis Associations (CEADE), aims to comprehensively understand the reality of axSpA patients from a holistic approach. A cross-sectional on-line survey of unselected patients with self-reported axSpA diagnosis from Spain was conducted. Participants were asked to report their diagnosis. Socio-demographic, disease characteristics and patient-reported outcomes (PROs) were compared between those patients self-reporting as nr-axSpA and r-axSpA.

**Results:** 634 axSpA patients participated. Mean age  $45.7 \pm 10.9$  years, 50.9% female and 36.1% university-educated. 35 (5.2%) self-reported as nr-axSpA. Compared to r-axSpA patients, those with nr-axSpA were more frequently women (48.6% vs 91.4%,  $p < 0.001$ ), had longer diagnostic delay ( $10.1 \pm 8.9$  vs  $8.5 \pm 7.6$  years), higher psychological distress (GHQ-12:  $7.5 \pm 4.9$  vs  $5.6 \pm 4.4$ ) and similar degree of disease activity (BASDAI:  $5.7 \pm 2.1$  vs  $5.7 \pm 2.0$ ), and unemployment rates (20.0% vs 21.6%). 20.0% of nr-axSpA received biologics vs 36.9% of r-axSpA,  $p = 0.043$ . Visits to the rheumatologist in the past year were similar in both groups ( $3.8 \pm 4.5$  vs  $3.2 \pm 3.8$ ), while GP visits were much higher within nr-axSpA ( $8.0 \pm 10.7$  vs  $4.9 \pm 13.3$ ,  $p = 0.003$ ).

**Conclusion:** For the first time, nr-axSpA characteristics and PROs have been analyzed from the patient's perspective. Both groups reported similar trends with the exception of nr-axSpA being more frequently women, younger, having longer diagnostic delay and lower use of biologic therapy.

**Key words:** ankylosing spondylitis, diagnosis-related groups, delayed diagnosis, pharmacologic therapy, patient-reported outcomes

## ***Introduction***

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that encompasses radiographic (r-axSpA, traditionally known as ankylosing spondylitis [AS]) and non-radiographic (nr-axSpA) forms. This inflammatory disease can lead to chronic pain, structural damage, and disability <sup>1</sup>. In particular, physical restrictions and worsening quality of life caused by the disease are closely related to the limitations that patients face in their professional, social and family spheres <sup>2,3</sup>.

During the last decades, there has been a tremendous increase in the volume of research on axSpA. However, its non-radiographic form has been the focus of attention in the recent years. Unlike AS, which was first described around 1900 <sup>4</sup>, nr-axSpA was first described in the 60s <sup>5</sup>. As a silent form of axSpA that courses without structural damage in sacroiliac joints or the rest of the spine, nr-axSpA diagnosis has implied a recent challenge for Rheumatology. Up to date, no study has been able to report the incidence or prevalence rates of nr-axSpA <sup>6</sup>.

Since the appearance of MRI scan and its possibilities, there has been an overemphasis on radiological criteria in the diagnosis of spondyloarthritis <sup>7</sup>. This has supported the advance in the research of the radiographic forms of axSpA at the expense of its non-radiographic forms. Either way, MRI by itself cannot serve as the touchstone to make a diagnosis of early axSpA due to limitations in both sensitivity and specificity, and because even an advanced imaging modality cannot capture the entire clinical spectrum of the condition <sup>8</sup>.

As a result, before the new Assessment of Spondyloarthritis International Society (ASAS) criteria, the previous classification criteria for SpA did not take into account the existence of non-radiographic forms, i.e. the 1984 Modified New York Criteria, the 1990 AMOR Criteria or the 1991 European Spondyloarthropathy Study Group criteria <sup>9</sup>. It has not been until 2009 when the ASAS published new classification criteria to reliably classify axSpA

in both its radiographic and non-radiographic forms <sup>10</sup> with solid sensibility and specificity (82.9% and 84.4% respectively) <sup>11</sup>. This is the first set of classification criteria that introduces nr-axSpA as a differentiated stage of the axSpA continuum <sup>7</sup>.

This way, it is not surprising that patients with r-axSpA and nr-axSpA experience a similar burden of disease, reporting similar levels of disease activity and functional limitation <sup>12</sup>, mental health <sup>13</sup> and overall level of quality of life <sup>14</sup>. Research has also informed of substantial work impact on nr-axSpA patients, not significantly different from those of r-axSpA patients <sup>15</sup>.

The concept of nr-axSpA was coined a decade ago after the development of ASAS classification criteria for axSpA. After this period, nr-axSpA entity seems to be well understood and implemented within rheumatology and drug regulatory agencies. Nevertheless, the understanding and knowledge of nr-axSpA by patients is unknown as specific research on the subject is non-existent. The purpose of the present study is to describe the characteristics and patient-reported outcomes (PROs) of patients who self-reported as nr-axSpA and compare them to those who self-reported as r-axSpA, using data from the Spanish Atlas.

## ***Materials and Methods***

### *Working Group*

Atlas 2017 is an initiative of the Spanish Federation of Spondylarthritis Associations (CEADE), carried out by Health & Territory Research (HTR) of the University of Seville and the Max Weber Institute, with the collaboration of the Spanish Society of Rheumatology (SER) and sponsored by Novartis Farmacéutica, Spain.



## *Design and Survey Development*

A patient questionnaire was designed for individuals suffering from axSpA based on expert opinion of a panel of rheumatologists and patient research partners with axSpA. The questionnaire collected data regarding the following areas: diagnosis, treatment, comorbidity, employment, functional limitation and psychological health.

The interest of the Atlas was to collect a real-world sample, rather than relying on patients collected in clinical settings, a method that is subject to sampling bias as patients recruited this way are typically “good patients” with better treatment adherence and in close contact with the health system. For this reason, the distribution of the patient survey was done through CEADE, which forwarded it to local axSpA-specific patient organizations. Participating patients could send the survey to family and friends with the disease, using a non-probabilistic snowball sampling method.

The online questionnaire surveying periods lasted from May 1 to August 15, 2016. After the validation and normalization of the information, the sample consisted of a total of 680 patients who responded to the majority of the questionnaire (completion rate was higher than 75%; see sample flow chart in Figure 1). An extensive report of the Atlas 2017 method can be consulted for further information <sup>16</sup>.

*Figure 1.* Flow chart of patients included in the study from the Spanish Atlas database.

Inclusion criteria were age of 18 years or older (adults), living in Spain during the survey and a self-reported diagnosis of axSpA. Diagnosis and type of condition was assessed by a multiple choice question at the beginning of the questionnaire which stated “Are you diagnosed with...?” followed by the following five options: “Ankylosing Spondylitis”, “Axial Spondyloarthritis”, “Non-radiographic Axial Spondyloarthritis”, “Peripheral Spondyloarthritis” and “None of the above”. The selection of the latter option (“None of the

above”) prevented the person from continuing to fill in the questionnaire and any data entered until that point was thus automatically discarded. For this study, patients who reported self-diagnosis of Peripheral Spondyloarthritis were removed from the sample. Two groups were considered, the r-axSpA group, comprised of those patients self-reporting diagnosis as either “Ankylosing Spondylitis” or “Axial Spondyloarthritis” and the nr-axSpA group, composed those declaring “Non-radiographic Axial Spondyloarthritis” as their diagnosis.

### *Supplementary indices*

In addition, a range of supplementary measures were collected in the questionnaire to assess specific areas:

1. *BASDAI (Bath Ankylosing Spondylitis Disease Activity Index)*: A validated self-administered questionnaire assessing disease activity in patients with axSpA <sup>17</sup>.
2. *Spinal Stiffness Index*: this index, based on the ASAS concept of spinal stiffness <sup>18</sup> was developed specifically for this study, assesses the degree of stiffness experienced by patients in the spinal column, distinguishing between the cervical, dorsal, and lumbar areas. Possible responses range from least to most affected column (1: without stiffness, 2: mild stiffness, 3: moderate stiffness, and 4: severe stiffness), total scores are obtained by adding together the responses in each of the three areas of the spine without weighting resulting in a scale ranging from 3 to 12.
3. *Functional Limitation Index*: this index, developed specifically for this study, assesses the degree of functional limitation in 18 daily life activities (dressing, bathing, showering, tying shoe laces, moving about the house, climbing stairs, getting out of bed, using the bathroom, shopping, preparing meals, eating, household cleaning, walking down the street, using public transportation, driving, going to the doctor, doing physical exercise, having sex). The activities were selected and validated by the scientific committee of the Atlas taking into

account the opinion of patient research partners. Each of these 18 daily life activities was assigned as 0 for no limitation, 1 low limitation, 2 medium limitation and 3 high limitations, resulting in values between 0 and 54. A total score from 0 and 18 was considered low limitation, between 18 and 36 medium limitation and between 36 and 54 high limitation.

4. *GHQ-12 (General Health Questionnaire–12)*: This questionnaire evaluates psychological distress using 12 items. For the present study, these were transformed into a dichotomous score (0-0-1-1), called the GHQ score. The cut-off point of 3 implied those with a score of 3 or more may be experiencing psychological distress <sup>19</sup>.

### *Statistical Analysis*

For the analyses, nr-axSpA group was compared with a r-axSpA group, combining the data from the AS and axSpA conditions (Figure 1). Sociodemographic, disease-related, employment status, healthcare utilization and treatment variables were compared between groups patients using Mann-Whitney, Kruskal-Wallis and Chi-square tests to assess the statistical significance of the observed differences between both groups.

### **Results**

A total of 680 people participated in the Atlas 2017 survey of which 46 participants who self-reported Peripheral axSpA were discarded, resulting in 634 being included in this study. For this sample of 634 participants, mean age was  $45.7 \pm 10.9$  years, 50.9% were female and 36.1% university-educated. 35 (5.5%) self-reported a diagnosis of nr-axSpA while the remaining 599 (94.5%) were classified as r-axSpA as they self-reported either AS (96.5%) or axSpA (3.5%). The vast majority of patients with self-reported nr-axSpA were women (91.4%), compared to 48.6% of women across patients with self-reported r-axSpA (Table 1).

Of the people with self-reported r-axSpA and nr-axSpA who completed the BASDAI scale the average score was exactly the same (5.7) which implies that the average disease activity was high (exceeding 4 which is the cut-off point indicating high disease activity score, according to rheumatologic standards) for both groups. The mean diagnostic delay declared by people with self-reported nr-axSpA was more than a year and a half longer than among those with self-reported r-axSpA (10.1 compared to 8.5). Patients with self-reported nr-axSpA showed higher levels of psychological distress, averaging at 7.5 at the GHQ-12 score whereas patients with other forms of self-reported r-axSpA averaged 5.6 (Table 1).

Distribution of self-reported r-axSpA and nr-axSpA patients regarding active and inactive population was equivalent, with similar unemployment rates. Out of the inactive population, two thirds of patients with self-reported nr-axSpA were on temporary sick leave at the moment of the survey compared to one quarter of patients with self-reported r-axSpA (Table 2).

Patients with self-reported nr-axSpA reported equivalent distributions regarding their disease-related appointments to healthcare specialists in the year prior to the survey with few exceptions. Patients with nr-axSpA reported an increased frequency of visits to orthopedic specialist and general practitioner, more than double to the physiotherapist and almost triple to the gastroenterologist (Table 3). Regarding the number of medical test taken by patients with self-reported nr-axSpA, similar frequencies were reported along both self-reported nr-axSpA and r-axSpA patients (Table 4).

With regard to pharmacologic treatments administered to patients, similar NSAID and DMARD, usage rates were reported for both groups (r-axSpA and nr-axSpA). With respect to biologic treatment, there were differences, as more than a third of self-reported r-axSpA patients declared to be taking biologics as opposed to the fifth of self-reported nr-axSpA patients that declared to be taking biologics (Table 5).

## *Discussion*

There is a discussion whether nr-axSpA and r-axSpA are different clinical entities or different stages of the same disease<sup>20</sup>. The fact that most of the studies report about 10% to 40% of patients with nr-axSpA to progress to r-axSpA over a period of two to ten years<sup>21</sup>, and that both entities share similar disease characteristics incline researchers towards the approach of being part of the same disease spectrum. According to published data, radiographic and non-radiographic forms of spondyloarthritis mainly differ in presence of substantial sacroiliac joints damage in r-axSpA forms and a higher proportion of females, young patients and elevated C-reactive protein (CRP) serum levels among nr-axSpA forms<sup>22</sup>. However, r-axSpA and nr-axSpA seem to have more aspects in common than differentials. Research from several cohorts such as the DESIR<sup>23</sup> or SPACE<sup>24</sup> have found similarities between both groups regarding symptom duration, age at onset of first symptoms, prevalence of HLA-B27 carriership<sup>25</sup>, patient-reported outcomes, and the presence of extra-articular or peripheral manifestations<sup>26,27</sup>. They also share a common course, as there are similarities in their disease development. As found out by the GESPIC cohort, both nr-axSpA and r-axSpA share factors associated to radiographic progression such as presence of syndesmophytes and acute phase reactants<sup>28</sup>. However, most of these previous data with regard to nr-axSpA comes from studies conducted in central or northern Europe and focused on the clinical aspects of the disease.

The Atlas places its focus of interest on Spain, a country in the Mediterranean zone, with a representative sample of the different Autonomous Communities and not only exploring clinical data but also considering functional limitation in daily life, work life and mental health, from patient's perspective. In this study, nr-axSpA account for only about 5% of all axSpA. One possible factor that could explain this low percentage is that the recruitment was done through the national patient organization (CEADE) and therefore, it is not possible to infer any consideration regarding the prevalence of nr-axSpA in relation to that of axSpA. Additionally,

women comprised a substantial percentage of the sample, which is common in studies conducted through online surveys<sup>29</sup>.

In spite of this, results of the present study including self-reported nr-axSpA and r-axSpA patients are consistent with published data collected directly in clinical settings. Patients with self-reported nr-axSpA informed of trends similar to that of patients with r-axSpA in the following aspects explored: sociodemographic, employment, healthcare utilization, disease activity, spinal stiffness and pharmacological treatments. Regarding socio-demographic, disease characteristics and PROs, the only significant observed differences were that compared with patients with r-axSpA, those with nr-axSpA had a higher proportion of females, greater functional limitation in daily life activities and were more frequently on temporary sick leave. In addition, a trend toward a longer diagnostic delay and worst mental health status in patients with nr-axSpA was also observed. We examined whether the presence of fibromyalgia could have affected PROs or diagnostic delay. However, it is unlikely that the presence of fibromyalgia could have altered our results because the percentage of fibromyalgia reported was within the published values of axSpA 30,31 and, additionally, there were no statistically significant differences in the distribution of fibromyalgia between the two groups.

Results of this Spanish Atlas survey are aligned with those of previous studies like that of the GESPIC cohort, in which, of all aspects assessed between radiographic and non-radiographic forms of axSpA, only a difference in gender ratios was found (women were more likely than men to have a diagnosis of nr-axSpA)<sup>22</sup>. Another study, also carried out in Germany in a sample of 100 patients (44% of them with a non-radiographic diagnosis) concluded that even if nr-axSpA and axSpA patients differed in signs of inflammation, they showed no differences regarding health status and disease activity. The same study also reported a higher prevalence of nr-axSpA in women<sup>12</sup>. On the other hand, patients with nr-axSpA in the Atlas reported higher functional limitation in daily activities. These results differ with data from other

populations such as SPACE or DESIR, in which no differences between groups were found for functional limitation. This may be explained by the different instrument employed to assess this outcome and also by the difficulties of patients with shorter disease duration to cope with the disease, as in our study the nr-axSpA group had a significantly shorter disease duration compared to that of SPACE and DESIR. In addition, patients with nr-axSpA reported to be on temporary sick leave more frequently than patients with r-axSpA. Similarly, to functional limitation, this could also be related to the difficulties to cope with the disease, as they are younger and so entering the labour market. Furthermore, in our study patients with self-reported nr-axSpA declared a higher level of psychological stress than their radiographic counterparts. However, sample size for that comparison was particularly low in the case of self-reported nr-axSpA so statistical results may be subject to sample bias, and can compromise the conclusions drawn from these results. In any case, other studies that have assessed psychological burden have not found statically significant differences between nr-axSpA and axSpA groups <sup>26</sup>.

Another aspect standing out in patients with self-reported nr-axSpA is a tendency for longer diagnostic delay with respect to those with self-reported r-axSpA, probably related to the absence of evidence of radiographic damage. Paradoxically, if we assume that some of the non-radiographic patients' progress to a radiographic stage, for sure a number of r-axSpA patients were only diagnosed at the beginning of their radiographic stage. This means that current r-axSpA patients could have go through a previous non-radiographic phase that was at the time totally unknown to rheumatologists and was, therefore, ignored and deprived of an early diagnosis and treatment.

As for the medical test used for diagnosis, both groups followed a similar diagnostic pathway with the exception of MRI scan, more frequently used in the nr-axSpA group. This is understandable as the rheumatologist with the support of the radiologist would probably run various scans in order to really determine whether or not there was radiographic damage.

Statistically significant differences also arise for the radionuclide scintigraphy option, although the frequency of use of this medical test is too low for drawing conclusions on a sample this size.

Regarding healthcare utilization, both groups reported similar profiles. However, the group self-reporting as nr-axSpA declared to visit general practitioners, orthopedic specialists and physiotherapists more frequently than their counterparts. This need to visit more medical specialists could be due to poorer disease outcomes. On the other hand, nr-axSpA patients reported less visits to psychologist/psychiatrist in the year prior to the survey, despite declaring greater psychological distress. This would point to an unmet need for psychological support for this group of patients.

Other important idea suggested by the data collected is that, despite that self-reported nr-axSpA patients have similar levels of disease activity and spinal stiffness than r-axSpA patients, they are not receiving biologic treatments at an equivalent rate.

### *Limitations*

However, this study has some limitations. First, all data of the survey was self-reported, and did not attempt to confirm participant diagnosis nor to support participant responses with clinician reported assessments. As such, clinical data such as the BASDAI or GHQ-12 scores, as well as the report of extra-articular manifestations may suffer from response bias. Nevertheless, the sample characteristics were consistent with previous cohorts including patients with confirmed axSpA and nr-axSpA<sup>12,22,25,32,33</sup>, and as the aim of the survey was to better understand the patient perspective, direct feedback was preferred. Secondly, as the sample was unselected there was no means to ensure the size of the nr-axSpA subgroup. The final sample had in total 35 patients with self-reported nr-axSpA, which precluded the possibilities of the inferential analysis. Low sample size of the nr-axSpA group could be due to



either misdiagnosis or patient misunderstanding of the disease, although women, well-represented in the sample, are more likely to be knowledgeable about their health status. Still, the descriptive analysis supports the goal of our study: to check the health and disease status of a neglected population of nr-axSpA patients.

### ***Conclusion***

For the first time, nr-axSpA disease characteristics and PROs, as well as patients' journey towards diagnosis, healthcare and treatments have been analysed from the patient's perspective. Results show a high burden of disease of nr-axSpA patients, comparable to that of the r-axSpA group, with similar work impact and use of healthcare resources, suggesting that both nr-axSpA and r-axSpA are associated to an equivalent level of suffering. Nr-axSpA patients reported the same level of disease activity, and similar levels of spinal stiffness, compared to r-axSpA patients, even if they are not receiving the same rate of biologics treatments.

Further research is needed on clinical aspects and impact on daily life aspects for a better understanding of the patient experience with the condition and the improvement of their healthcare, management and quality of life.

### ***References***

1. Sieper, J. & Poddubnyy, D. Axial spondyloarthritis. *Lancet* **390**, 73–84 (2017).
2. Song, Y., Wang, C. & Chen, H. Functional limitation and associated factors in outpatients with ankylosing spondylitis in Southwest China. *Clin. Rheumatol.* **36**, 871–7 (2017).
3. Shen, C.-C. *et al.* Risk of Psychiatric Disorders following Ankylosing Spondylitis: A Nationwide Population-based Retrospective Cohort Study. *J. Rheumatol.* **43**, 625–31 (2016).

4. Sieper, J. & van der Heijde, D. Nonradiographic Axial Spondyloarthritis: New Definition of and Old Disease? *Arthritis Rheum.* **65**, 543–551 (2013).
5. Khan, M. A., Valkenburg, H. A. & Cats, A. Spondylitic disease without radiologic evidence of sacroiliitis in relatives of HLA-B27 positive ankylosing spondylitis patients. *Arthritis Rheum.* **28**, 40–43 (1985).
6. Bohn, R., Cooney, M., Deodhar, A., Curtis, J. R. & Golembesky, A. Incidence and prevalence of axial spondyloarthritis: Methodologic challenges and gaps in the literature. *Clin. Exp. Rheumatol.* **36**, 263–274 (2018).
7. Malaviya, A. N., Rawat, R., Agrawal, N. & Patil, N. S. The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology. *Int. J. Rheumatol.* **2017**, 1–9 (2017).
8. Lukas, C., Cyteval, C., Dougados, M. & Weber, U. MRI for diagnosis of axial spondyloarthritis: Major advance with critical limitations ‘Not everything that glisters is gold (standard)’. *RMD Open* **4**, 1–9 (2018).
9. Lockwood, M. M. & Gensler, L. S. Nonradiographic axial spondyloarthritis. *Best Pract. Res. Clin. Rheumatol.* **31**, 816–829 (2017).
10. Banegas-Illescas, M. E., López-Menéndez, C., Rozas-Rodríguez, M. L. & Fernández-Quintero, R. M. New ASAS criteria for the diagnosis of spondyloarthritis: Diagnosing sacroiliitis by magnetic resonance imaging. *Radiologia* **56**, 7–15 (2014).
11. Rudwaleit, M. *et al.* The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann. Rheum. Dis.* **68**, 770–6 (2009).
12. Boonen, A. *et al.* The burden of non-radiographic axial spondyloarthritis. *Semin.*

- Arthritis Rheum.* **44**, 556–562 (2015).
13. Poddubnyy, D. *et al.* Similarities and differences between nonradiographic and radiographic axial spondyloarthritis. *Curr. Opin. Rheumatol.* **26**, 377–383 (2014).
  14. Kiltz, U. *et al.* Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? *Arthritis Care Res.* **64**, 1415–1422 (2012).
  15. van Hoesen, L., Boonen, A. E. R. C. H., Hazes, J. M. W. & Weel, A. E. A. M. Work outcome in yet undiagnosed patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis; results of a cross-sectional study among patients with chronic low back pain. *Arthritis Res. Ther.* **19**, 1–8 (2017).
  16. Garrido-Cumbrera, M. *et al.* Atlas of axial spondyloarthritis in Spain 2017: Study design and population. *Reumatol. Clin.* **15**, 127–132 (2019).
  17. Garrett, S. *et al.* A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J. Rheumatol.* **21**, 2286–91 (1994).
  18. Zochling, J. *et al.* ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann. Rheum. Dis.* **65**, 442–52 (2006).
  19. Cano, A. *et al.* Mental Health Screening in Primary Care: A Comparison of 3 Brief Measures of Psychological Distress. *Prim Care Companion J Clin Psychiatry* **3**, 206–210 (2001).
  20. Deodhar, A., Strand, V., Kay, J. & Braun, J. The term ‘non-radiographic axial spondyloarthritis’ is much more important to classify than to diagnose patients with axial spondyloarthritis. *Ann. Rheum. Dis.* **75**, 791–794 (2016).
  21. Protopopov, M. & Poddubnyy, D. Radiographic progression in non-radiographic axial

- spondyloarthritis. *Expert Rev. Clin. Immunol.* **14**, 525–533 (2018).
22. Poddubnyy, D. *et al.* Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. *Ann. Rheum. Dis.* **70**, 1369–1374 (2011).
  23. Dougados, M. *et al.* The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. *Jt. Bone Spine* **78**, 598–603 (2011).
  24. van Lunteren, M. *et al.* In Early Axial Spondyloarthritis, Increasing Disease Activity Is Associated with Worsening of Health-related Quality of Life over Time. *J. Rheumatol.* **45**, 779–784 (2018).
  25. Baraliakos, X. & Braun, J. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: What are the similarities and differences? *RMD Open* **1**, 8–11 (2015).
  26. Erol, K. *et al.* Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis. *Acta Reumatol. Port.* **43**, 32–39 (2018).
  27. de Winter, J. J., van Mens, L. J., van der Heijde, D., Landewé, R. & Baeten, D. L. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: A meta-analysis. *Arthritis Res. Ther.* **18**, 1–11 (2016).
  28. Poddubnyy, D. *et al.* Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. *Arthritis Rheum.* **64**, 1388–1398 (2012).
  29. Smith, G. & Smith, W. G. Does gender influence online survey participation?: A record-linkage analysis of university faculty online survey response behavior. (2008).

30. Salaffi, F. et al. Fibromyalgia in patients with axial spondyloarthritis: Epidemiological profile and effect on measures of disease activity. *Rheumatol. Int.* **34**, 1103–1110 (2014).
31. Rifbjerg-Madsen, S. et al. Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey. *PLoS One* **12**, 1–16 (2017).
32. Malaviya, A. N., Kalyani, A., Rawat, R. & Gogia, S. B. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi. *Int. J. Rheum. Dis.* **18**, 736–741 (2015).
33. Poddubnyy, D. & Sieper, J. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. *Curr. Opin. Rheumatol.* **26**, 377–383 (2014).

### Tables

*Table 1.* Sociodemographic characteristics and patient-reported outcomes of patients with self-reported nr-axSpA (N: 35, unless other specified) and r-axSpA (N: 599, unless other specified)

<i>Variable</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
Age (years)	42.1 ± 8.8	46.0 ± 10.9	0.045*
Gender (female)	32 (91.4)	291 (48.6)	<0.001** *
Education level (University)	17 (48.6)	212 (35.4)	0.351

Marital status (Married)	20 (57.1)	434 (72.5)	0.223
Disease duration	14.1 ± 10.1 N: 18	21.8 ± 12.1 N: 486	<0.001** *
HLA B27	20 (64.5) N: 31	350 (75.9) N: 461	0.155
BASDAI (0-10)	5.7 ± 2.1 N: 18	5.7 ± 2.0 N: 368	0.792
High BASDAI (≥ 4)	15 (83.3) N: 18	294 (79.9) N: 368	0.721
Spinal Stiffness Index (3-12)	6.5 ± 2.5 N: 24	7.5 ± 2.7 N: 437	0.053
Functional Limitation Index (0-54)	45.6 ± 10.4	42.1 ± 10.0 N: 531	0.007**
GHQ-12 (0-12)	7.5 ± 4.9 N: 20	5.6 ± 4.4 N: 418	0.087
Anxiety	6 (17.1)	116 (19.4)	0.746
Depression	5 (14.3)	86 (14.4)	0.991
<b>Fibromyalgia</b>	<b>4 (11.4)</b>	<b>44 (7.3)</b>	<b>0.375</b>
Diagnostic delay (years)	10.1 ± 8.9 N: 32	8.5 ± 7.6 N: 482	0.193

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

Table 2. Employment status of patients with self-reported nr-axSpA (N: 35) and r-axSpA (N: 599)

<i>Employment Status</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
<i>Active</i>	20 (57.1)	370 (64.5)	
Employed	16 (80.0)	290 (78.4)	0.864
Unemployed	4 (20.0)	80 (21.6)	
<i>Inactive</i>	15 (42.9)	204 (35.5)	
Temporary sick leave	10 (66.6)	47 (23.0)	0.006**
Permanent sick leave	3 (20.0)	55 (27.0)	
Retired	0 (0.0)	59 (28.9)	
Early retired	0 (0.0)	9 (4.4)	
Homemaker	1 (6.7)	26 (12.7)	
Student	1 (6.7)	8 (3.9)	

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

Table 3. Specialists appointments in the past 12 months of patients with self-reported nr-axSpA (N: 35) and r-axSpA (N: 599)

<i>Specialist Appointments</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
--------------------------------	---	---	----------------

Rheumatologist	3.8 ± 4.5	3.2 ± 3.8	0.377
General Practitioner	8.0 ± 10.7	4.9 ± 13.3	0.003**
Clinical nurse	2.0 ± 4.3	2.1 ± 8.4	0.873
Orthopedic specialist	0.9 ± 2.0	0.5 ± 2.0	0.003**
Physiotherapist	14.3 ± 28.3	6.4 ± 19.0	0.012*
Ophthalmologist	1.0 ± 1.8	0.8 ± 2.2	0.135
Pulmonologist	0.2 ± 0.6	0.2 ± 0.8	0.462
Cardiologist	0.2 ± 1.0	0.2 ± 0.8	0.574
Psychologist	1.4 ± 3.3	2.0 ± 9.9	0.034*
Gastroenterologist	0.142 ± 0.4	0.058 ± 0.5	0.002**

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

Table 4. Medical test undertaken before diagnosis of patients with self-reported nr-axSpA (N: 35) and r-axSpA (N: 599)

<i>Medical test</i>	<i>Self-reported nr-axSpA (N: 35) mean ± SD or n(%)</i>	<i>Self-reported r-axSpA (N: 599) mean ± SD or n(%)</i>	<i>p-value</i>
X-rays	3.8 ± 4.5	3.2 ± 3.8	0.377
MRI	1.7 ± 2.5	0.6 ± 1.4	<0.001***
Ultrasound scan	0.4 ± 0.7	0.3 ± 0.8	0.051
Radionuclide scintigraphy	0.2 ± 0.5	0.1 ± 0.4	0.014*
CT scan	0.03 ± 0.2	0.04 ± 0.3	0.911



Blood test	3.8 ± 5.4	3.1 ± 3.8	0.947
Urine test	1.9 ± 2.8	1.9 ± 2.9	0.794

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

*Table 5.* Pharmacological treatment undertaken in the past 12 months of patients with self-reported nr-axSpA (N: 35, unless other specified) and r-axSpA (N: 599, unless other specified)

<i>Pharmacological Treatment</i>	<i>Self-reported nr-axSpA (N: 35)</i>	<i>Self-reported r-axSpA (N: 599)</i>	<i>p-value</i>
	<i>mean ± SD or n(%)</i>	<i>mean ± SD or n(%)</i>	
NSAID <sup>†</sup>	22 (62.9)	340 (56.8)	0.479
DMARD <sup>‡</sup>	5 (14.3)	131 (21.9)	0.288
Biologic	7 (20.0)	221 (36.9)	0.043*

<sup>†</sup>NSAID: Non-Steroidal Anti-Inflammatory Drug

<sup>‡</sup>DMARD: Disease-Modifying Anti-Rheumatic Drug

\*The association is significant at the 0.05 level

\*\*The association is significant at the 0.01 level

\*\*\*The association is significant at the 0.001 level

### ***Figure legends***

*Figure 1.* Flow chart of patients included in the study from the Spanish Atlas database.

AxSpA: axial Spondyloarthritis

Nr-axSpA: non-radiographic axial Spondyloarthritis